Arcus Biosciences Hits New 52-Week High at $31.72, Up 91.61%

Arcus Biosciences, Inc. has reached a significant milestone by hitting a new 52-week high of USD 31.72 on June 30, 2026. This achievement marks a remarkable increase from its 52-week low of USD 7.92, showcasing a substantial growth trajectory over the past year. In the context of its industry, Arcus operates within the Pharmaceuticals & Biotechnology sector, which is characterized by rapid innovation and development. The company, with a market capitalization of USD 2,542 million, is classified as a small-cap entity. Over the past year, Arcus has demonstrated impressive performance, achieving a 91.61% increase, significantly outpacing the S&P 500's performance of 20.86%. Despite its recent price surge, Arcus Biosciences is currently loss-making, reflected in its negative P/E ratio and a return on equity of -55.94%. The company does not offer a dividend, and its debt-to-equity ratio stands at -1.38, indicating a unique financial structure. As Arcus continues to navigate the competitive landscape of biotechnology, its recent price performance highlights its evolving market position.